Sanli Pharmaceutical: Mengalihkan 16 izin edar obat dengan biaya transfer sebesar 2 juta yuan

Sanli Pharmaceutical Announcement, the company and Guizhou Hanfang Pharmaceutical Co., Ltd. signed the “Drug Marketing Authorization Holder Transfer Agreement,” agreeing that Hanfang Pharmaceutical will transfer its marketing authorization and related rights for 16 drugs to the company, among which Cisplatin Sodium Chloride Injection is the core product of this transfer. The total transfer price (including tax) is 2 million RMB. This transaction does not constitute an associated transaction, nor does it constitute a major asset reorganization. According to the “Shanghai Stock Exchange Stock Listing Rules,” “Articles of Association,” and other relevant regulations, the matters involved in this transaction do not need to be submitted for approval by the board of directors and shareholders’ meeting. The change of drug marketing authorization holder still requires approval from the drug regulatory authorities, and there is uncertainty about whether the change can be completed smoothly.